Single dose of trastuzumab kick starts immune response in certain breast cancers
(Case Western Reserve University) A tumor's immune response to a single dose of the HER2 inhibitor trastuzumab predicted which patients with HER2-positive breast cancer would respond to the drug on a more long-term basis, according to the results of a study published recently in Clinical Cancer Research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 29, 2016 Category: Cancer & Oncology Source Type: news

Relationship Between HER2 Expression and Trastuzumab BenefitRelationship Between HER2 Expression and Trastuzumab Benefit
Will your patient benefit from trastuzumab? New research using quantitative RNA analysis of HER2 may help you find out. Breast Cancer Research (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - February 26, 2016 Category: Pathology Tags: Hematology-Oncology Journal Article Source Type: news

Treating HER2 Lung Cancers: The EUHER2 CohortTreating HER2 Lung Cancers: The EUHER2 Cohort
Is trastuzumab beneficial in combination with chemotherapy for advanced HER2-positive advanced NSCLC? Annals of Oncology (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - February 26, 2016 Category: Pathology Tags: Hematology-Oncology Journal Article Source Type: news

What Women with Metastatic Breast Cancer Should...
Herceptin (trastuzumab) is a chemotherapy infusion medication approved to treat adjuvant and metastatic breast cancer. Learn about how it works. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - February 12, 2016 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

Trastuzumab emtansine saves costs in HER2+ mBC
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2016 Category: Drugs & Pharmacology Source Type: news

ALTTO No More Than a Detour for HER2+ Breast CancerALTTO No More Than a Detour for HER2+ Breast Cancer
Dr Lidia Schapira weighs in on the results of the ALTTO trial in HER2-positive breast cancer in which dual therapy using trastuzumab plus lapatinib proved disappointing. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 25, 2016 Category: Consumer Health News Tags: Hematology-Oncology Viewpoint Source Type: news

Herceptin Affirmed, Anthracyclines Questioned in Major TrialHerceptin Affirmed, Anthracyclines Questioned in Major Trial
The landmark BIRCG-006 trial that helped establish trastuzumab as a standard for early-stage HER2-positive breast cancer continues to stir debate over which chemotherapy to pair it with. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 17, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Cardiac Meds Appear to Protect Heart From Herceptin DamageCardiac Meds Appear to Protect Heart From Herceptin Damage
Surprising result seen with early breast cancer patients. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 15, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

10 Years On, Herceptin Still Rides High (CME/CE)
(MedPage Today) -- Final analysis of 'landmark' trial finds sustained efficacy (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - December 12, 2015 Category: Journals (General) Source Type: news

Neratinib Keeps Benefiting Herceptin-Treated Breast CancerNeratinib Keeps Benefiting Herceptin-Treated Breast Cancer
New results from the ExteNET study of the investigational drug neratinib following adjuvant trastuzumab chemotherapy confirm a benefit of the agent beyond the previously reported 2-year results. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 11, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

T-DM1 improved overall survival for heavily pretreated patients with HER2-pos breast cancer
Among patients with HER2-positive, metastatic breast cancer that had progressed despite treatment with two or more forms of HER2-targeted therapy (trastuzumab [Herceptin] and lapatinib [Tykerb]), median overall survival was increased for those treated with trastuzumab emtansine (T-DM1 [Kadcyla]) compared with those who received treatment of physician's choice, according to results from the phase III TH3RESA clinical trial. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 11, 2015 Category: Science Source Type: news

T-DM1 improved overall survival for heavily pretreated patients with HER2-positive breast cancer
(American Association for Cancer Research) Among patients with HER2-positive, metastatic breast cancer that had progressed despite treatment with two or more forms of HER2-targeted therapy (trastuzumab [Herceptin] and lapatinib [Tykerb]), median overall survival was increased for those treated with trastuzumab emtansine (T-DM1 [Kadcyla]) compared with those who received treatment of physician's choice, according to results from the phase III TH3RESA clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 11, 2015 Category: Cancer & Oncology Source Type: news

Prevention Curbs Herceptin Cardiac Effect (CME/CE)
(MedPage Today) -- But randomized trial fails to meet primary endpoint (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - December 10, 2015 Category: Journals (General) Source Type: news

Dual HER2 Inhibition Flops as Adjuvant Breast Ca Tx (CME/CE)
(MedPage Today) -- Lapatinib-trastuzumab no better than trastuzumab alone (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 23, 2015 Category: Hematology Source Type: news

Will immunotherapy add value to chemotherapy for HER-2 positive gastric cancer?
(European Organisation for Research and Treatment of Cancer) EORTC trial 1203 -- Integration of trastuzumab, with or without pertuzumab, into perioperative chemotherapy of HER-2 positive stomach cancer, is open for recruitment for patients with early, HER-2 positive gastric cancer. This phase II, randomized EORTC study was developed to investigate the added value of a perioperative treatment regimen which includes HER-2 targeting drugs for patients with gastric and gastro-esophageal junction cancers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 13, 2015 Category: Global & Universal Source Type: news

PharmaMar's novel ADC demonstrates anticancer activity in HER2-expressing
(Pharmamar) PharmaMar announced that its novel Antibody-Drug Conjugate (ADC) demonstrates strong anticancer activity in vitro and in vivo against tumors expressing HER2 derived from breast, gastric and ovarian cancers. The novel ADC MI130004 consists of a new marine-derived tubulin inhibitor that is covalently bound to the HER2 antibody trastuzumab via a non-hydrolysable linker. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 6, 2015 Category: Global & Universal Source Type: news

Delhi HC blocks Reliance from launching copy of Roche's breast cancer drug
Delhi High Court has blocked Reliance Life Sciences from launching copies of Swiss drug maker Roche’s breast cancer drug trastuzmab, branded as Herceptin. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 4, 2015 Category: Pharmaceuticals Source Type: news

Ovarian cancer drug 'can help with some types of prostate cancer'
Conclusion Prostate cancer is common in the UK, so news of new treatment options is always welcome. However, this study does not show for certain that olaparib works better than no treatment, even for men with the DNA repair mutations identified in the study as responding to treatment. The first problem is the lack of a comparison group. We can see what happened to the men who took the drug, but not what might have happened if they had not taken it, or if they'd taken another type of treatment not already tried. And most of the men treated did not get any benefit from the drug. Only 16 of the 49 men assessed showed any s...
Source: NHS News Feed - October 29, 2015 Category: Consumer Health News Tags: Cancer Medication Older people Source Type: news

HER2-Positive Breast CA Patients Prosper on Solo Chemo (CME/CE)
(MedPage Today) -- Patients with elevated tumor-infiltrating lymphocytes do better without additional Herceptin (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 15, 2015 Category: Hematology Source Type: news

Scottish Medicines Consortium approves herceptin to treat patients with gastric cancer
The Scottish Medicines Consortium (SMC) has granted approval for herceptin (trastuzumab) for routine use in the NHS to treat patients in Scotland with an advanced and incurable form of gastric cancer (stomach and gastro-oesophageal). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 13, 2015 Category: Pharmaceuticals Source Type: news

Key oncologist Dennis Slamon to be honoured in Dublin
Doctor’s discovery of breast cancer drug Herceptin saved lives of countless women (Source: The Irish Times - Health)
Source: The Irish Times - Health - October 8, 2015 Category: Consumer Health News Source Type: news

Perjeta® gets regulatory green light for use in early HER2-positive breast cancer prior to surgery
Perjeta (pertuzumab) regimen nearly doubled number of women whose tumours are eradicated versus standard treatment (Source: Pharmacy Europe)
Source: Pharmacy Europe - September 29, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Personalised medicine Practical therapeutics Oncology Research breast cancer her2 HER2-positive breast cancer herceptin Latest News NEOSPHERE perjeta TRYPHAENA Source Type: news

Gene Test Finds Which Breast Cancer Patients Can Skip Chemo
Many women with early-stage breast cancer can skip chemotherapy without hurting their odds of beating the disease — good news from a major study that shows the value of a gene-activity test to gauge each patient’s risk. The test accurately identified a group of women whose cancers are so likely to respond to hormone-blocking drugs that adding chemo would do little if any good while exposing them to side effects and other health risks. In the study, women who skipped chemo based on the test had less than a 1 percent chance of cancer recurring far away, such as the liver or lungs, within the next five years. &ldq...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - September 28, 2015 Category: Consumer Health News Authors: miketoole Tags: Health Local News Breast Cancer Chemotherapy Source Type: news

A Conversation With: Cori Bargmann Puts Her Mind to How the Brain Works
For a neurobiologist at Rockefeller University, a mission to help lead a president’s initiative starts with a search for the needed tools. (Source: NYT Health)
Source: NYT Health - September 21, 2015 Category: Consumer Health News Authors: CLAUDIA DREIFUS Tags: Genetics and Heredity Rockefeller University Brain Initiative/Activity Map Project (US Health and Human Services) Nobel Prizes Herceptin (Drug) Bargmann, Cornelia I Worms Source Type: news

Breast cancer patient who planned her funeral celebrates tying the knot after beating the disease... and 'miracle' daughter conceived during treatment is bridesmaid
Teressa Llewellyn, 44, from Yorkshire, became the third woman in the world to become pregnant while taking the anti-cancer drug Herceptin and credits her 'miracle baby' Keira with giving her the will to survive. (Source: the Mail online | Health)
Source: the Mail online | Health - August 10, 2015 Category: Consumer Health News Source Type: news

Roche's Perjeta regimen approved in Europe for use before surgery in early stage aggressive breast cancer
Roche today announced that the European Commission (EC) has approved the use of Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for the neoadjuvant treatment (use before surgery) of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. (Source: Roche Media News)
Source: Roche Media News - July 31, 2015 Category: Pharmaceuticals Source Type: news

Roche's Perjeta regimen approved in Europe for use before surgery in early stage aggressive breast cancer
Roche today announced that the European Commission (EC) has approved the use of Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for the neoadjuvant treatment (use before surgery) of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. (Source: Roche Investor Update)
Source: Roche Investor Update - July 31, 2015 Category: Pharmaceuticals Source Type: news

trastuzumab, Herceptin
Title: trastuzumab, HerceptinCategory: MedicationsCreated: 12/14/2000 12:00:00 AMLast Editorial Review: 7/27/2015 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - July 27, 2015 Category: Cancer & Oncology Source Type: news

Trastuzumab emtansine: lower AE-related costs in Canada
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 1, 2015 Category: Drugs & Pharmacology Source Type: news

Samsung’s Bioepis considers Nasdaq IPO, seeks funding
(Reuters) – South Korean Samsung‘s (LON:BC94) Bioepis Co Ltd, a developer of generic versions of biotech drugs, said it was considering a Nasdaq IPO – a move that comes as it seeks about $1.3 billion for product development and as the Samsung Group makes a bigger push into biopharmaceuticals. Highlighting growth opportunities for its biopharmaceuticals business may be a tactic by the Samsung Group to win support for a planned merger of two affiliates that would strengthen control for its founding Lee family, analysts said. A proposed $8 billion takeover of construction firm Samsung C&T Corp ...
Source: Mass Device - June 29, 2015 Category: Medical Equipment Authors: MassDevice Tags: Biotech Business/Financial News Wall Street Beat Samsung Bioepis Co Ltd Samsung Electronics Co. Ltd. Source Type: news

EU CHMP recommends Roche’s Perjeta for pre-surgery use in breast cancer
The European Union (EU) Committee for Medicinal Products for Human Use (CHMP) has recommended for approval Roche's Perjeta along with Herceptin and chemotherapy for neoadjuvant treatment of adult patients with HER2-positive early breast cancer. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 29, 2015 Category: Pharmaceuticals Source Type: news

Oncolytic Viral Therapy Using Reovirus
Current mainstays in cancer treatment such as chemotherapy, radiation therapy, hormonal manipulation, and even targeted therapies such as Trastuzumab (herceptin) for breast cancer or Iressa (gefitinib) for non-small cell lung cancer among others are limited by lack of efficacy, cellular resistance, and toxicity. Dose escalation and combination therapies designed to overcome resistance and increase efficacy are limited by a narrow therapeutic index. Oncolytic viruses are one such group of new biological therapeutics that appears to have a wide spectrum of anticancer activity with minimal human toxicity. (Source: Springer pr...
Source: Springer protocols feed by Cancer Research - June 27, 2015 Category: Cancer & Oncology Source Type: news

Roche’s Perjeta recommended for approval in EU for use before surgery in HER2-positive early breast cancer
Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission approves the use of Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for the neoadjuvant treatment (use before surgery) of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. (Source: Roche Media News)
Source: Roche Media News - June 26, 2015 Category: Pharmaceuticals Source Type: news

Roche’s Perjeta recommended for approval in EU for use before surgery in HER2-positive early breast cancer
Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission approves the use of Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for the neoadjuvant treatment (use before surgery) of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. (Source: Roche Investor Update)
Source: Roche Investor Update - June 26, 2015 Category: Pharmaceuticals Source Type: news

UCLA receives $1 million from Revlon to fund breast cancer research
UCLA has received a $1 million donation from Revlon that will support the Revlon/UCLA Women’s Cancer Research Program and further the company’s long-standing commitment to eradicating women’s cancers. The gift was announced by Revlon CEO Lorenzo Delpani, chairman Ronald O. Perelman and global brand ambassador Halle Berry at an event honoring Dr. Dennis Slamon, a member of the UCLA Jonsson Comprehensive Cancer Center and director of the Revlon/UCLA Breast Cancer Center Director for his outstanding achievements in cancer research. “We have made tremendous advancements in the field of breast cancer tre...
Source: UCLA Newsroom: Health Sciences - June 8, 2015 Category: Universities & Medical Training Source Type: news

Marc Benioff and Gates Foundation's Desmond-Hellmann Agree: Digital Health So Far Is Pitiful
Marc Benioff and Sue Desmond-Hellman appear onstage together at Techonomy Bio 2015. (Photo by Rebecca Greenfield) By Adrienne Jane Burke For an onstage conversation at Techonomy Bio 2015 about how science is advancing human progress around the world and where the greatest challenges still remain, Susan Desmond-Hellmann and Marc Benioff might seem an unlikely pair. She's an oncologist accomplished in biotech, academia and, now, the nonprofit sector as CEO of the Bill and Melinda Gates Foundation. Benioff is chairman of the customer relationship management software company Salesforce.com. But, as the two agreed here on Wed...
Source: Science - The Huffington Post - June 4, 2015 Category: Science Source Type: news

Roche’s Perjeta regimen helped people with HER2-positive early breast cancer live longer without their disease returning or getting worse compared to Herceptin and chemotherapy
Roche today announced new results from the Phase II NeoSphere study. The results suggest that Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and docetaxel chemotherapy given prior to surgery reduced the risk of disease getting worse and increased the time people lived without their cancer returning compared to Herceptin and chemotherapy in people with HER2-positive early breast cancer (eBC). (Source: Roche Media News)
Source: Roche Media News - June 1, 2015 Category: Pharmaceuticals Source Type: news

Roche’s Perjeta regimen helped people with HER2-positive early breast cancer live longer without their disease returning or getting worse compared to Herceptin and chemotherapy
Roche today announced new results from the Phase II NeoSphere study. The results suggest that Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and docetaxel chemotherapy given prior to surgery reduced the risk of disease getting worse and increased the time people lived without their cancer returning compared to Herceptin and chemotherapy in people with HER2-positive early breast cancer (eBC). (Source: Roche Investor Update)
Source: Roche Investor Update - June 1, 2015 Category: Pharmaceuticals Source Type: news

Master switch for cancer-causing HER2 protein identified
Herceptin has been touted as a wonder drug for women with HER2-positive breast cancer, an aggressive form of the disease that is fueled by excess production of the HER2 protein. However, not all of these patients respond to the drug, and many who do respond eventually acquire resistance. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 28, 2015 Category: Science Source Type: news

Mayo Clinic-led research team identifies master switch for cancer-causing HER2 protein
(Mayo Clinic) Herceptin has been touted as a wonder drug for women with HER2-positive breast cancer, an aggressive form of the disease that is fueled by excess production of the HER2 protein. However, not all of these patients respond to the drug, and many who do respond eventually acquire resistance. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 27, 2015 Category: Cancer & Oncology Source Type: news

Mayo Clinic-led Team Identifies Master Switch for Cancer-Causing HER2 Protein
ROCHESTER, Minn. — Herceptin has been touted as a wonder drug for women with HER2-positive breast cancer, an aggressive form of the disease that is fueled by excess production of the HER2 protein. However, not all of these patients respond to the drug, and many who do respond eventually acquire resistance. A team of researchers [...] (Source: Mayo Clinic Rochester News)
Source: Mayo Clinic Rochester News - April 27, 2015 Category: Hospital Management Source Type: news

Precision medicine is coming, but not anytime soon
President Obama’s announcement of a Precision Medicine Initiative was one of the few items in this year’s State of the Union address to garner bipartisan support. And for good reason. Precision medicine, also known as personalized medicine, offers the promise of health care — from prevention to diagnosis to treatment — based on your unique DNA profile. Who wouldn’t want that? We’ve already had a taste of precision medicine. Relatively low-tech therapies like eyeglasses, orthotic devices, allergy treatments, and blood transfusions have long been personalized for the individual. Genetic an...
Source: New Harvard Health Information - March 26, 2015 Category: Consumer Health News Authors: Beverly Merz Tags: Health care personalized health care precision medicine Source Type: news

Genentech delves into apps to link with breast cancer patients
Over years of cancer drug research, Genentech Inc. has kept a keen watch on patients: how they respond to drugs in a clinical trial, for example, or what patients need in a next-generation drug. Yet even as the South San Francisco-based biotech unit of Swiss drug giant Roche developed some of the best-selling and effective cancer drugs — Avastin and Herceptin among them — it heard from patients that the medications themselves were not enough. Breast cancer patients, in particular, wanted to… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 3, 2015 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

HER2-Positive Metastatic Breast Cancer: New Standard of CareHER2-Positive Metastatic Breast Cancer: New Standard of Care
Combining two targeted agents, trastuzumab and pertuzumab, with docetaxel resulted in unprecedented survival in HER2-positive metastatic breast cancer. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 20, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

New mechanism of acquired resistance to breast cancer drugs
In the search for new approaches to treat ERBB2 positive breast cancers that have become drug-resistant, researchers have discovered a novel cancer resistance mechanism. "Approximately 25% of breast cancers overexpress and depend on the protein ERBB2 for survival," said the lead investigator. "Current therapies take advantage of this by using targeted drugs such as Trastuzumab or Lapatinib to specifically inhibit ERBB2, but eventually they become ineffective as the cancer develops resistance to those drugs." (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 2, 2015 Category: Science Source Type: news

Herceptin May Benefit Some Women With Early Breast Cancer
Title: Herceptin May Benefit Some Women With Early Breast CancerCategory: Health NewsCreated: 1/7/2015 12:00:00 AMLast Editorial Review: 1/8/2015 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - January 8, 2015 Category: Cancer & Oncology Source Type: news

Herceptin May Benefit Some Women With Early Breast Cancer
Drug-chemo combo yields low rate of recurrence after three years, study says (Source: WebMD Health)
Source: WebMD Health - January 8, 2015 Category: Consumer Health News Source Type: news

Herceptin May Benefit Some Women With Early Breast Cancer
Drug-chemo combo yields low rate of recurrence after three years, study says (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 8, 2015 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Gynecology, Nursing, Oncology, Pharmacy, News, Source Type: news

Potential Practice Change in Small HER2-+ Breast CancersPotential Practice Change in Small HER2-+ Breast Cancers
Less intensive chemotherapy combined with trastuzumab resulted in a very high rate of disease-free survival and suggests that more chemo is not needed in stage I disease treated with systemic therapy. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 7, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Herceptin May Benefit Some Women with Early Breast Cancer
Drug-chemo combo yields low rate of recurrence after three years, study saysSource: HealthDay Related MedlinePlus Pages: Breast Cancer, Cancer Chemotherapy (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - January 7, 2015 Category: Consumer Health News Source Type: news